Crofelemer meets Phase III diarrhea endpoint

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) and partner Napo Pharmaceuticals Inc. (South San Francisco, Calif.) said twice-daily crofelemer for 28 days met the primary endpoint in the Phase III ADVENT tr...